Business Context and Reporting Period
Company: Better Choice Company Inc. (Ticker: BTTR, NYSE American)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Business Overview: A pet health and wellness company operating under the Halo brand, selling premium pet food, treats, and supplements. The company utilizes an outsourced manufacturing model and sells through Digital (e-commerce), International, and Brick & Mortar channels. In 2024, the company exited its Direct-to-Consumer (DTC) channel and certain unprofitable Brick & Mortar partners to improve profitability.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $34.98 million | $38.59 million |
| Gross Profit | $12.99 million | $11.80 million |
| Gross Margin | 37.1% | 30.6% |
| Operating Loss | $(5.97) million | $(21.18) million |
| Net Loss | $(0.17) million | $(22.77) million |
| Cash and Equivalents (Year End) | $3.07 million | $4.46 million |
| Total Debt (Outstanding) | $2.41 million | $4.62 million |
| Stockholders' Equity | $8.65 million | $2.98 million |
Note: The 2024 Net Loss was significantly reduced by a $6.2 million non-cash gain on the extinguishment of debt and accounts payable.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% to $35.0 million, driven by the strategic exit of the DTC channel (June 2024) and the removal of unprofitable Brick & Mortar customers (Petco stores and Pet Supplies Plus) in late 2023.
- Margin Expansion: Gross margin improved to 37% from 31%, attributed to improved pricing from manufacturers and portfolio rationalization.
- Debt Restructuring: The company settled litigation with Alphia Inc., resulting in the forgiveness of a $5.0 million term loan, $0.5 million in accrued interest, and up to $2.6 million in accounts payable. This generated a $6.2 million gain on extinguishment.
- Operating Expenses: Total operating expenses decreased 43% to $19.0 million. This includes a $5.5 million reduction in SG&A (due to lower headcount and marketing spend) and the absence of the $8.5 million intangible asset impairment charge recorded in 2023.
- Capital Structure: The company completed a public equity offering in July 2024 raising approximately $5.3 million and repurchased 102,597 shares of common stock under a $5.0 million authorization.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
Management is shifting focus to a "digital-first" strategy, reallocating media investment to Amazon and Chewy platforms. The company is pursuing an all-stock acquisition of SRx Health Solutions, Inc. (a Canadian specialty pharmacy network) valued at approximately $80 million, subject to regulatory and court approvals. The combined entity aims to become a global health and wellness company.
Risks and Contingencies
- Going Concern: The company has incurred recurring losses and has a significant accumulated deficit. The auditor has issued a "Going Concern" opinion, stating substantial doubt exists regarding the company's ability to continue operations for the next 12 months without additional financing.
- Listing Compliance: The company received notices of noncompliance from NYSE American regarding minimum stockholders' equity ($4.0 million required vs. $1.1 million reported in Q1 2024) and stock price. A compliance plan is in place, but delisting remains a risk.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding revenue recognition data accuracy and IT general controls (access, change management, cybersecurity).
- Concentration Risk: Approximately 79% of inventory purchases were sourced from three vendors in 2024. Two customers represented 86% of accounts receivable.
Unusual Items
The $6.2 million gain on extinguishment of debt and accounts payable is a non-recurring item that significantly impacted the bottom line, masking the underlying operating loss of $5.97 million.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional capital or achieve profitability within the next 12 months to avoid insolvency.
- SRx Acquisition: Monitor the status of the SRx Health Solutions amalgamation, including regulatory approvals and the risk of NYSE delisting if initial listing standards are not met post-merger.
- Listing Compliance: Track progress on the NYSE American compliance plan to avoid delisting, which would severely impact liquidity and stock price.
- Internal Controls: Review the remediation plan for material weaknesses in revenue recognition and IT controls to ensure future financial reporting reliability.
- Revenue Concentration: Assess the risk associated with reliance on a small number of suppliers and customers, particularly in the International channel (China).